Public Employees Retirement System of Ohio lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 163,673 shares of the medical research company's stock after selling 8,143 shares during the quarter. Public Employees Retirement System of Ohio's holdings in Thermo Fisher Scientific were worth $85,148,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Barrett & Company Inc. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $28,000. FPC Investment Advisory Inc. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. Pillar Financial Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $29,000. Endeavor Private Wealth Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth approximately $30,000. Finally, Noble Wealth Management PBC purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 89.23% of the company's stock.
Thermo Fisher Scientific Price Performance
TMO stock traded up $0.63 during trading on Wednesday, reaching $404.18. 839,145 shares of the company were exchanged, compared to its average volume of 1,868,905. Thermo Fisher Scientific Inc. has a 52-week low of $390.50 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a market cap of $152.57 billion, a P/E ratio of 24.45, a PEG ratio of 2.99 and a beta of 0.82. The stock's 50 day moving average price is $437.74 and its 200 day moving average price is $502.70.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. The company's quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.11 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.
Analyst Ratings Changes
TMO has been the topic of a number of research reports. Citigroup lowered their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Morgan Stanley lifted their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Argus decreased their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. UBS Group dropped their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Finally, Royal Bank of Canada lowered their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $607.43.
Read Our Latest Stock Report on Thermo Fisher Scientific
Insider Transactions at Thermo Fisher Scientific
In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares of the company's stock, valued at $59,506,950.58. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,075 shares of company stock valued at $7,305,942 in the last ninety days. Corporate insiders own 0.33% of the company's stock.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
